SAGE Therapeutics (SAGE) Reports Q2 Loss of $0.36
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
August 7, 2018 6:30 AM EDTConditional acceptance granted by U.S. Food and Drug Administration (FDA) for the proprietary name ZULRESSO for Sages intravenous formulation of brexanolone
Continuing to execute commercial build and launch readiness for ZULRESSO (brexanolone injection) in postpartum depression ahead of PDUFA target date of December 19, 2018
Accelerating breakthrough pivotal program for SAGE-217 in depression with key trial milestones expected in 4Q 2018
Progressed clinical pipeline with SAGE-718 Phase 1 multiple ascending dose and SAGE-324 Phase 1 single ascending dose trial initiations and planned SAGE-217 Phase 2 trial initiation in bipolar depression
... More